Pfizer has granted  SatRx , a company belonging to Russian pharmaceutical investment and R&D group  ChemRar Hi-Tech Centre , exclusive development and marketing rights to for its DPP(1)-IVi compound, PF-00734200.

Pfizer granted exclusive worldwide rights (excluding China) to develop and commercialize PF-00734200 as monotherapy or in combination with certain other. Pfizer will receive royalties and milestone payments based on commercialization activities. The agreement was developed as partial fulfillment of a Memorandum of Understanding reached in March 2011, under which Pfizer and ChemRar agreed to explore collaborations focused on R&D and commercialization of innovative compounds and vaccines to treat cardiometabolic, infectious and oncologic diseases in Russia and other countries.

"We welcome this licensing agreement between SatRx and Pfizer. SatRx is going to register the new drug to the Russian market and will further establish breakthrough therapies for treating diabetes synergistically combining DPP-IVi with TGR5 agonists and other novel small molecule drug candidates in its R&D portfolio,” said Nikolay Savchuk, board member of ChemRar.

Yulia Baybikova, general manager of SatRx, added, "This licensing agreement with Pfizer provides SatRx with essential background for development of fully innovative tools to tune the metabolism of patients with T2D and obesity. Synergistic actions of DPP-IVi and proprietary new SatRx molecules active in the incretin metabolic cascade will provide significant therapeutic benefits and promises to increase patient compliance and quality of life.”